- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01870492
Improving Patient Access to Stroke Therapy Study (IMPACT)
Limited access is a major hurdle in the treatment of AIS; many hospitals, especially rural hospitals, do not have the infrastructure or medical support to effectively treat AIS patients.5 Failure to recognize the signs and symptoms of stroke by the patient and/or emergency medical services (EMS) is another barrier to the timely treatment of AIS. Several studies, including the Paul Coverdell National Acute Stroke Registry (PCNASR), have reported low rates of adherence to stroke care guidelines, suggesting that many AIS patients do not receive proper treatment according to established guidelines. Thus, there remains an increasing need to assess and address the barriers that prevent patient access to proper AIS treatment.
Annually, approximately 20,000 patients are discharged from Wisconsin hospitals with the diagnosis of stroke and an estimated 4,000 patients die from stroke each year in WI. To date, there have been no statewide studies initiated in Wisconsin to assess the regional barriers to the treatment of AIS patients with thrombolytic or endovascular therapy, and many hospitals do not routinely collect and analyze AIS patient data.
The goal of the Improving Patient Access to Stroke Therapy (IMPACT) pilot study is to engage community hospitals statewide to identify the regional barriers to AIS therapy in WI.
연구 개요
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
Wisconsin
-
Milwaukee, Wisconsin, 미국, 53226
- Medical College of Wisconsin
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Age > 18 years
- Clinical diagnosis of acute ischemic stroke or transient ischemic attack (TIA)
- ICD-9-CM code indicative of stroke or TIA
Exclusion Criteria:
- Clinical diagnosis of intracerebral hemorrhage or subarachnoid hemorrhage
- Stroke or TIA occurred while patient was hospitalized
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
---|---|
Acute ischemic stroke or TIA
Patients presenting with acute ischemic stroke or transient ischemic attack and underwent treatment using Activase and/or endovascular therapy.
|
Patients treated with Activase
다른 이름들:
Patients treated with endovascular therapy, such as IA-tPA, mechanical thrombectomy, etc for acute ischemic stroke or transient ischemic attack.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Identification of regional pre-hospital, hospital, and community barriers to stroke therapy
기간: At end of study (12 months)
|
At end of study (12 months)
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
Total number of stroke patients treated with acute stroke therapy
기간: At end of study (12 months)
|
At end of study (12 months)
|
Total number of stroke patients eligible to receive Activase® versus patients eligible but did not receive Activase®
기간: At end of study (12 months)
|
At end of study (12 months)
|
Use of endovascular therapy in patients who received Activase® versus patients who did not receive Activase®
기간: At end of study (12 months)
|
At end of study (12 months)
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Osama O Zaidat, MD, MS, Medical College Wisconsin
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Activase에 대한 임상 시험
-
Seattle Children's HospitalThe Hospital for Sick Children; Medical College of Wisconsin; McMaster University; Alberta... 그리고 다른 협력자들종료됨
-
Richard Chang, M.D.National Institutes of Health Clinical Center (CC)완전한
-
Daniel HanleyNational Institute of Neurological Disorders and Stroke (NINDS); Genentech, Inc.; Emissary...완전한